In This Section

Program: Sunday, October 26

Wednesday, Oct. 22Thursday, Oct. 23Friday, Oct. 24Saturday, Oct. 25

Please note that this conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. All podium presentation sessions will be recorded and made available as an on-demand program after the conference. All presentations are scheduled to be live, in-person presentations at the date and time (U.S. ET) specified in the program. Poster presentations will not be available for viewing on-demand.

Program in progress.

*-Short talk from proffered abstract

Sunday, October 26

Sunday, October 26

Continental Breakfast

7-8 a.m. | Ballroom Foyer and Bolyston Street Hallway

Plenary Session 7: Cellular and Adoptive Therapy

8-9:40 a.m. | Level 3, Ballroom AB

Session Cochairs: Marco Donia, Copenhagen University Hospital, Herlev, Denmark and Matthew Frigault, Massachusetts General Hospital, Boston, Massachusetts

  • 8:05 a.m. | Tumor-infiltrating lymphocyte therapy in 2025: State of the art and what’s next
    Marco Donia
  • 8:35 a.m.
    Matthew Frigault
  • 9:05 a.m. | Transposon-based BAFF CAR-T cells (LMY-920) for treatment of Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Lymphoma (CLL), and Multiple Myeloma (MM)*
    Paolo Caimi, Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
  • 9:20 a.m. | Panel Discussion

Break

9:40-10 a.m.

Plenary Session 8: Synthetic Lethality

10-11:40 a.m. | Level 3, Ballroom AB

Session Cochairs: Adam S. Crystal, Tango Therapeutics, Boston, Massachusetts and Victoria Sánchez Perez, Vall D’Hebron Institute of Oncology, Barcelona, Spain

  • 10:05 a.m. | PELO-HBS1L: ribosome rescue and mRNA decay as a novel synthetic lethal axis
    Edmond M. Chan, Columbia University Irving Medical Center, New York, New York
  • 10:26 a.m. | DNA repair and synthetic lethality
    Peter S. Hammerman, MoMa Therapeutics, Cambridge, Massachusetts
  • 10:47 a.m. | Synthetic lethality beyond DDR pathway
    Francisca Vazquez, Broad Institute, Cambridge, Massachusetts
  • 11:08 a.m. | PRMT5: Bench to bedside
    Adam S. Crystal
  • 11:29 a.m. | A pan-cancer map of paralog dependencies reveals novel synthetic lethal targets and biomarker-defined vulnerabilities*
    William Sellers, Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, Massachusetts

Break

11:40 a.m.-12 p.m.

Plenary Session 9: Omics to Guide Precision Therapy

12-1:40 p.m. | Level 3, Ballroom AB

Session Cochairs: Peter Horak, German Cancer Research Center, Heidelberg, Germany

  • 12:05 p.m. | The road to implementation of Personlised Cancer Medicine in Europe: DRUP-like clincial trials, PCM-4EU, PRIME-ROSE and the Joint Action on PCM
    Hans Gelderblom, Leiden University Medical Centre, Leiden, The Netherlands
  • 12:30 p.m. | Rare cancers, tumor agnostic therapies, and real world data
    David M. Thomas, University of New South Wales, Sydney, Australia
  • 12:55 p.m. | Integrative multi-omics profiling identifies therapeutic opportunities in rare
    Peter Horak
  • 1:20 p.m. | Panel Discussion

Closing Comments and Departure

1:40-1:45 p.m. | Level 3, Ballroom AB